Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
NCT07588139Phase 1Completed
- Sponsor
- Incyte
- Start
- May 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of povorcitinib and ruxolitinib cream (3 cohorts), sponsored by Incyte. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started May 2026; status: completed.
02
Drugs
povorcitinibruxolitinib cream
Beyond the preview
Go deeper on NCT07588139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588139.